The University Hospital

Dr. med. Dr. (MBChB) Hathal Haddad

Dr. med. Dr. (MBChB) Hathal Haddad

Senior physician for interventional radiotherapy (IRT) and brachytherapy

Interventional radiotherapy and brachytherapy (prostate cancer, breast cancer, liver tumors, skin tumors, gynecological tumors, head and neck tumors, keloids)

Contact

Phone number: +49 7071 29-82165

E-mail address: hathal.haddad@med.uni-tuebingen.de

Clinic / Institute / Center

  • Senior physician at the University Clinic for Radiation Oncology. Specialties: Interventional radiotherapy and brachytherapy

    Specialist in radiotherapy. Member of the Royal College of Radiologists (MRCR). Active member of the German Brachytherapy Working Group (DEGRO) and the German Stereotactic Working Group. Active member of the European Working Groups for Brachytherapy (GEC-ESTRO). Active member of the Global Brachytherapy Collaboration of the American Brachytherapy Society. Active member of the Brachytherapy Working Group of the Middle East Society for Radiation Oncologist (MESTRO)

  • AG Interventional Radiotherapy
  • 2023: MESTRO Winning Competition in Abstract Section
  • 2023: Award from Menofia University in Egypt for conducting the first HDR brachytherapy of prostate cancer in Egypt
  • Comparative Evaluation of a Medical Large Language Model in Answering Real-World Radiation Oncology Questions: A Multicenter Observational Study. https://preprints.jmir.org/preprint/69752/accepted
  • Evaluating the role of adjuvant therapy in improving outcomes for patients with lymph node-positive penile cancer following surgical management. https://doi.org/10.1016/j.urolonc.2025.04.003
  • The current status of brachytherapy in Europe - A GEC-ESTRO Brachy-HERO survey. https://doi.org/10.1016/j.ctro.2024.100883
  • Radiotherapy of prostate cancer in the primary situation. DOI: 10.1055/a-2307-4799
  • Integration of Artificial Intelligence in Interstitial HDR Brachytherapy for Liver Tumors. https://doi.org/10.1016/S0167-8140(24)00841-7
  • Application of a Radiopaque Viscous Hydrogel Spacer for Prostate Cancer Radiation Therapy: A Prospective Phase 2 Study. Pract Radiat Oncol. 2024 Jan-Feb;14(1):57-64. doi: 10.1016/j.prro.2023.05.013. Epub 2023 Oct 3. PMID: 37791943.
  • Dose Distribution of High Dose-Rate and Low Dose-Rate ProstateBrachytherapy at Different Intervals-Impact of a Hydrogel Spacer andProstate Volume. Cancers (Basel). 2023 Feb 22;15(5):1396.
  • Evaluation of Autocontouring in the Interstitial HDR Brachytherapy of LiverTumors. Brachytherapy. 2022 Nov. S48-S49
  • Focal injection of a radiopaque viscous spacer before focal brachytherapy as re-irradiation for locally recurrent prostate cancer.
  • Permanent interstitial brachytherapy for prostate cancer implementingneoadjuvant prostatic artery embolization. 2022May-Jun;21(3):308- 316
  • Long-Term Comparative Study on the Local Tumor Control ofDifferent Ablation Technologies in Primary and Secondary LiverMalignancies. Journal of Personalized Medicine. 2022 Mar 9;12(3):430.
  • GEC-ESTRO ACROP prostate brachytherapy guidelines. Radiotherapy and Oncology. 2022 Feb; 167:244-251
  • Interstitial single fraction brachytherapy for malignant pulmonary tumors. Radiation Therapy and Oncology. 2021May;197(5):416-422
  • Personalized Image-Guided Therapies for Local Malignancies:Interdisciplinary Options for Interventional Radiology and InterventionalRadiotherapy. Frontiers in Oncology. 2021 Apr 1;11:616058.
  • Analysis of the image quality of two different I-125 seed models usingTRUS, MR and CT. H. Radiotherapy and Oncology. May 2021. p181-S182.
  • Dosimetric Comparison of Different Dose Calculation Algorithms in CT-BasedInterstitial HDR Brachytherapy. Brachytherapy2019 May. S114
  • Dosimetric Verification of HDR Brachytherapy Treatment Plans of ThreeDifferent Entities Based on Measurements with a 2D-Array. Brachytherapy 2019 May, S113.
  • Publications